Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mycophenolate sodium controlled release - Novartis

Drug Profile

Mycophenolate sodium controlled release - Novartis

Alternative Names: EC-MPS; ERL 080; ERL 080A; Mycophenolic acid - Novartis; Myfortic

Latest Information Update: 10 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; University of Pittsburgh
  • Class Benzofurans; Small molecules; Urologics
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lupus nephritis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal transplant rejection
  • No development reported Heart transplant rejection; Liver transplant rejection; Lupus nephritis

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for mycophenolate sodium in USA and Europe (Novartis 20-F filed in 2017)
  • 09 Jan 2014 First generic equivalent available in USA for Renal transplant rejection
  • 18 Nov 2009 Novartis completes a phase II trial in Lupus nephritis in Hungary, France, Great Britain, Greece, Denmark, Italy and Spain (EudraCT2006-002107-13)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top